These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
211 related articles for article (PubMed ID: 34708587)
1. Jadomycins: A potential chemotherapy for multi-drug resistant metastatic breast cancer. Bonitto EP; McKeown BT; Goralski KB Pharmacol Res Perspect; 2021 Dec; 9(6):e00886. PubMed ID: 34708587 [TBL] [Abstract][Full Text] [Related]
2. Jadomycins are cytotoxic to ABCB1-, ABCC1-, and ABCG2-overexpressing MCF7 breast cancer cells. Issa ME; Hall SR; Dupuis SN; Graham CL; Jakeman DL; Goralski KB Anticancer Drugs; 2014 Mar; 25(3):255-69. PubMed ID: 24231527 [TBL] [Abstract][Full Text] [Related]
3. Jadomycins Inhibit Type II Topoisomerases and Promote DNA Damage and Apoptosis in Multidrug-Resistant Triple-Negative Breast Cancer Cells. Hall SR; Toulany J; Bennett LG; Martinez-Farina CF; Robertson AW; Jakeman DL; Goralski KB J Pharmacol Exp Ther; 2017 Nov; 363(2):196-210. PubMed ID: 28904004 [TBL] [Abstract][Full Text] [Related]
4. Isolation of a jadomycin incorporating L-ornithine, analysis of antimicrobial activity and jadomycin reactive oxygen species (ROS) generation in MDA-MB-231 breast cancer cells. Forget SM; Robertson AW; Hall SR; MacLeod JM; Overy DP; Kerr RG; Goralski KB; Jakeman DL J Antibiot (Tokyo); 2018 Aug; 71(8):722-730. PubMed ID: 29700425 [TBL] [Abstract][Full Text] [Related]
5. Biosynthesis, synthetic studies, and biological activities of the jadomycin alkaloids and related analogues. de Koning CB; Ngwira KJ; Rousseau AL Alkaloids Chem Biol; 2020; 84():125-199. PubMed ID: 32416952 [TBL] [Abstract][Full Text] [Related]
6. Jadomycin breast cancer cytotoxicity is mediated by a copper-dependent, reactive oxygen species-inducing mechanism. Hall SR; Blundon HL; Ladda MA; Robertson AW; Martinez-Farina CF; Jakeman DL; Goralski KB Pharmacol Res Perspect; 2015 Mar; 3(2):e00110. PubMed ID: 25729577 [TBL] [Abstract][Full Text] [Related]
7. Synthesis and in Vitro Cytotoxicity Evaluation of Jadomycins. Iwasaki E; Shimizu Y; Akagi Y; Komatsu T Chem Pharm Bull (Tokyo); 2023; 71(9):730-733. PubMed ID: 37661378 [TBL] [Abstract][Full Text] [Related]
12. Novel and expanded jadomycins incorporating non-proteogenic amino acids. Jakeman DL; Graham CL; Reid TR Bioorg Med Chem Lett; 2005 Dec; 15(23):5280-3. PubMed ID: 16185863 [TBL] [Abstract][Full Text] [Related]
13. Adipocytes promote breast cancer resistance to chemotherapy, a process amplified by obesity: role of the major vault protein (MVP). Lehuédé C; Li X; Dauvillier S; Vaysse C; Franchet C; Clement E; Esteve D; Longué M; Chaltiel L; Le Gonidec S; Lazar I; Geneste A; Dumontet C; Valet P; Nieto L; Fallone F; Muller C Breast Cancer Res; 2019 Jan; 21(1):7. PubMed ID: 30654824 [TBL] [Abstract][Full Text] [Related]
14. Cross-resistance studies of isogenic drug-resistant breast tumor cell lines support recent clinical evidence suggesting that sensitivity to paclitaxel may be strongly compromised by prior doxorubicin exposure. Guo B; Villeneuve DJ; Hembruff SL; Kirwan AF; Blais DE; Bonin M; Parissenti AM Breast Cancer Res Treat; 2004 May; 85(1):31-51. PubMed ID: 15039596 [TBL] [Abstract][Full Text] [Related]
16. Jadomycins derived from the assimilation and incorporation of norvaline and norleucine. Dupuis SN; Veinot T; Monro SM; Douglas SE; Syvitski RT; Goralski KB; McFarland SA; Jakeman DL J Nat Prod; 2011 Nov; 74(11):2420-4. PubMed ID: 22050382 [TBL] [Abstract][Full Text] [Related]
17. Culture conditions improving the production of jadomycin B. Jakeman DL; Graham CL; Young W; Vining LC J Ind Microbiol Biotechnol; 2006 Sep; 33(9):767-72. PubMed ID: 16568271 [TBL] [Abstract][Full Text] [Related]
18. Gefitinib reverses chemotherapy resistance in gefitinib-insensitive multidrug resistant cancer cells expressing ATP-binding cassette family protein. Yang CH; Huang CJ; Yang CS; Chu YC; Cheng AL; Whang-Peng J; Yang PC Cancer Res; 2005 Aug; 65(15):6943-9. PubMed ID: 16061679 [TBL] [Abstract][Full Text] [Related]
19. Folic Acid-Modified Nanoerythrocyte for Codelivery of Paclitaxel and Tariquidar to Overcome Breast Cancer Multidrug Resistance. Zhong P; Chen X; Guo R; Chen X; Chen Z; Wei C; Li Y; Wang W; Zhou Y; Qin L Mol Pharm; 2020 Apr; 17(4):1114-1126. PubMed ID: 32176509 [TBL] [Abstract][Full Text] [Related]
20. Multidrug resistance mediated by the breast cancer resistance protein BCRP (ABCG2). Doyle L; Ross DD Oncogene; 2003 Oct; 22(47):7340-58. PubMed ID: 14576842 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]